Nodular lymphocyte-predominant Hodgkin’s lymphoma

Nogová, Lucia; Diehl, Volker; Engert, Andreas

doi:10.1007/s11899-006-0019-2

Cited by 3 publications

(3 citation statements)

References 25 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although NLPHL has a better overall treatment outcome than cHL (reflecting at least in part frequent low‐stage and low‐volume disease at diagnosis), risk factors associated with an inferior overall survival (OS) and progression‐free survival (PFS) include advanced‐stage disease, 1,6 presence of B symptoms 1 and mediastinal lymphadenopathy 7 in both children and adults. Variant histology has been shown to be an independent predictor of poor treatment outcome, advanced‐stage disease and higher risk of recurrent disease in both children and adults 8–11 .…”

Section: Diagnosis and Stagingmentioning

confidence: 99%

Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute

et al. 2022

View full text Add to dashboard Cite

Summary A consensus statement for the management for patients of all ages with all stages of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) — All StAGEs — is proposed by representatives of the UK National Cancer Research Institute (NCRI) Hodgkin lymphoma study group and the Children's Cancer & Leukaemia Group. Based on current practices and published evidence, a consensus has been reached regarding diagnosis, staging and risk‐ik7 stratified management which includes active surveillance, low‐ and standard‐dose immunochemotherapy and radiotherapy.

show abstract

Section: Diagnosis and Stagingmentioning

confidence: 99%

Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There have been few prior studies evaluating the outcome of patients with advanced-stage NLPHL. 11,12 The largest study reported by the German Hodgkin lymphoma study group (GHSG) described 82 patients with advanced-stage NLPHL (stage-IIB with risk factors and stage-III to IV) who were evaluated as part of a larger retrospective study comparing patients with all stages of NLPHL or CHL treated on GHSG trials from 1988 to 2002. 10 Different treatment protocols like ABVD, COPP and BEACOP with or without radiation were used in all the trails.…”

Section: Discussionmentioning

confidence: 99%

“…The Median follow up was 42 months, and there has been no relapse or transformation. 12 Treatment protocol for advanced disease is controversial. A recent review by Fanale et al, demonstrated an excellent outcome in patients treated with CHOP based protocol.…”

Section: Discussionmentioning

confidence: 99%

Nodular Lymphocytic Predominant Hodgkin Lymphoma (NLPHL); Treatment Outcome Study in a Tertiary Care Cancer Hospital in Pakistan

Shah

Bakar

et al. 2022

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the demographics, clinical characteristics and treatment outcomes of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL) patients treated at our hospital. Study Design: Retrospective longitudinal study. Place and Duration of Study: Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan from 1996 to 2016. Methodology: We collected clinical data of all the cases of HL diagnosed over twenty years (between 1996 and 2016) from our electronic hospital information system (HIS). A total of 3426 HL patients were identified, out of whom the pathologically confirmed diagnosis of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL) was identified. Results: In this study, eighty-four patients were studied. The majority of the patients were male (80%). B symptoms were present in 35%. There were 24% patients in stage-I (n=20/84), 33% in stage-II (n=28/84), 12% in stage III (n=10/84) and 31% in stage IV (n=26/84). Hence, early-stage was seen in 57% (n=48/84) and advanced stage was 43% (n=36/84) respectively. The Median follows up time was 30 months (range: 1-60 months). Patients were treated with chemotherapy in most cases (48%), radiotherapy alone in 14% cases, and combined modality (chemotherapy and radiotherapy) was used in 38% patients. The estimated 5–year disease-free survival was 73% and overall survival was 86%. Autologous stem cell transplant was done in only one patient whose disease had transformed from NLPHL to T-rich cell B cell lymphoma. Conclusion: This study confirmed the divergent features of NLPHL with a comparatively good long-term prognosis. Most patients achieved an excellent response to first-line therapy. There was...

show abstract